SOURCE: Evogene

Evogene

June 04, 2013 09:00 ET

Evogene Announces Confidential Submission of Draft Registration Statement for U.S. Public Offering

REHOVOT, ISRAEL--(Marketwired - Jun 4, 2013) - Evogene Ltd. ("Evogene") (TASE: EVGN) today announced plans to conduct a registered public offering of its ordinary shares in the United States. The offering is expected to commence, subject to market conditions, after the U.S. Securities and Exchange Commission completes its review process initiated by Evogene's confidential submission of a draft registration statement. However, there can be no assurances with regard to the timing or the completion of the offering.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact Information

  • Contact:
    Karen Mazor
    Evogene
    Director, Public and Investor Relations
    T: +972-8-931-1900, ext. 664
    Email Contact